Thromb Haemost 1997; 77(03): 562-567
DOI: 10.1055/s-0038-1656006
Platelets
Schattauer GmbH Stuttgart

Antiplatelet Effect of FK633, a Platelet Glycoprotein Ilb/IIIa Antagonist, on Thrombus Formation and Vascular Patency after Thrombolysis in the Injured Hamster Carotid Artery

Takehiro Kaida
1   Department of Pharmacology, Gifu University School of Medicine, Gifu, Japan
2   Department of Otorhinolaryngology, Gifu University School of Medicine, Gifu, Japan
,
Hiroyuki Matsuno
1   Department of Pharmacology, Gifu University School of Medicine, Gifu, Japan
,
Masayuki Niwa
1   Department of Pharmacology, Gifu University School of Medicine, Gifu, Japan
,
Osamu Kozawa
1   Department of Pharmacology, Gifu University School of Medicine, Gifu, Japan
,
Hideo Miyata
2   Department of Otorhinolaryngology, Gifu University School of Medicine, Gifu, Japan
,
Toshihiko Uematsu
1   Department of Pharmacology, Gifu University School of Medicine, Gifu, Japan
› Author Affiliations
Further Information

Publication History

Received 19 March 1996

Accepted after resubmission21 November 1996

Publication Date:
11 July 2018 (online)

Zoom Image

Summary

The antithrombotic and restenosis-preventing effects of FK633, an inhibitor of platelet aggregation via binding to the glycoprotein (GP) Ilb/IIIa receptor, were studied. IC50 value of FK633 against platelet aggregation ex vivo induced by 2.5 |iM adenosine diphosphate (ADP) was 5.4 X 10"7 M as determined using hamster platelet rich plasma. The inhibitory effect was also investigated in vivo on thrombus formation at the carotid arterial wall injured by a modified catheter. As a control, the left carotid artery was injured and the time required to develop a thrombotic occlusion (3.9 ±1.1 min, mean ± S.E.M., n = 18) was determined. Then, the right carotid artery of the same animal was injured while a continuous intravenous (i.v.) infusion of FK633 was administered at doses of 0 (saline), 0.1,0.3 or 1.0 mg/kg/h. The time to occlusion was dose-dependently prolonged. In a separate experiment, 10% of the total tPA dose (0.52 mg/kg) was injected into the injured artery as a bolus and the remaining was infused i.v. at a constant rate for 30 min. When FK633 (0.3 or 1.0 mg/kg/h) was infused together with tPA, late patency of the reperfused artery was much improved as compared with that of treatment with tPA alone. Bleeding time, measured at the end of the tPA infusion, was markedly prolonged when the higher dose of FK633 (1.0 mg/kg/h) was coadministered, however coadministration of the lower dose of FK633 (0.3 mg/kg/h) was almost without prolongation on the bleeding time, despite a significant effect on the vascular patency after thrombolysis. Next, neointima formation was evaluated 2 weeks after the vascular injury. When FK633 (0.3 mg/kg/h) was continuously infused i. v. by an implanted osmotic pump for 3,7 or 14 days after the vascular injury, the neointimal area formation was significantly suppressed in the treatment groups for 7 or 14 days. These findings suggest that FK633 inhibits platelet activation in the injured artery and improves vascular patency after thrombolysis with tPA with a concomitant suppression of neointima formation.

Crossref Cited-by logo
Article Citations